title: Exercise and drug therapy alter recovery from labyrinth lesion in humans.
abstract: Acute unilateral vestibular failure is characterized by rotatory vertigo, horizontal-rotatory nystagmus, and postural imbalance, all of which last from days to weeks. These signs and symptoms are caused by a vestibular tone imbalance between the two labyrinths. Recovery results from a combination of peripheral restoration of labyrinthine function (usually incomplete) and central vestibular compensation (CVC) of the vestibular tone imbalance. Acute unilateral failure is most often caused by vestibular neuritis, which is most likely due to the reactivation of a latent HSV-1 infection. Therefore, therapeutic strategies to improve the outcome of VN are theoretically based on two principles: (a) vestibular exercises and drugs to improve CVC and (b) drug treatment of the assumed viral inflammation. The following conclusions can be drawn from studies in animals and/or humans: (1) There is strong evidence that vestibular exercises may improve vestibulo-spinal compensation. These exercises should begin as early as possible after symptom onset. Moreover, slower exercises are likely to be more effective than faster exercises because slower ones seem to depend more on the vestibular system. (2) Despite extensive data from animal experiments indicating that drugs have a favorable effect on CVC, this has not been clinically proven and thus cannot be recommended yet. (3) Preliminary results of an interim analysis from an ongoing randomized, prospective study showed that methylprednisolone (plus an antiviral agent?) may be useful for improving peripheral vestibular function in vestibular neuritis.
authors.affiliation: Department of Neurology, University of Munich, Klinikum Grosshadern, Germany. mstrupp@nefo.med.uni-muenchen.de
authors.forename: M
authors.initials: M
authors.lastname: Strupp
authors.forename: V
authors.initials: V
authors.lastname: Arbusow
authors.forename: T
authors.initials: T
authors.lastname: Brandt
mesh_terms: D000212:Acyclovir / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D007758:Ear, Inner / Q000187:drug effects / Q000473:pathology*; D015444:Exercise; D006801:Humans; D008775:Methylprednisolone / Q000494:pharmacology / Q000627:therapeutic use*; D014717:Vertigo / Q000188:drug therapy* / Q000503:physiopathology*; D020338:Vestibular Neuronitis / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D000212:Acyclovir; D008775:Methylprednisolone